摘要:
探讨恩替卡韦加复方鳖甲软肝片对乙肝肝硬化的效果评价.在CNKI等数据库检索相关文献,应用REVMAN5.3软件对各研究系统评价.纳入6篇研究,合并分析,ALT:合并效应Z =2.03,p=0.04,WMD=-4.75,95%CI(-9.35,-0.16).AIB∶Z=2.82,P=0.005.WMD=1.46,95%CI(0.45,2.47);HBVDNA的转阴率:Z=0.66,P=0.51,>0.05,合并比值比OR=1.47,95%CI(0.47,4.62);HA∶Z =2.47,P=0.01,SMD=-1.53,95%CI(-2.74,-0.32);IV-C∶Z=3.43,P=0.0006,SMD=-1.37,95%CI(-2.15,-0.59);LN:合并Z=3.74,p=0.0002,SMD=-1.08,95%CI(-1.64,-0.51);PCⅢ:合并Z=3.61,p=0.0003,SMD=-0.97,95%CI(-1.49,-0.44).在改善肝功能和肝纤维化上,恩替卡韦联合组优于单用恩替卡韦组,但对HBVDNA转阴率无统计学差异.